Epilepsy: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett m (→Treatment) |
imported>Robert Badgett m (→Treatment) |
||
| Line 2: | Line 2: | ||
==Treatment== | ==Treatment== | ||
A [[randomized controlled trial]] concluded:<ref name="pmid17382828">{{cite journal |author=Marson AG, Al-Kharusi AM, Alwaidh M, ''et al'' |title=The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial |journal=Lancet |volume=369 |issue=9566 |pages=1016–26 |year=2007 |pmid=17382828 |doi=10.1016/S0140-6736(07)60461-9}}</ref><ref name="pmid17903391">{{cite journal |author=Marson AG, Appleton R, Baker GA, ''et al'' |title=A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial |journal=Health technology assessment (Winchester, England) |volume=11 |issue=37 |pages=1–154 |year=2007 |pmid=17903391 |doi=}}</ref> | A [[randomized controlled trial]] concluded:<ref name="pmid17382828">{{cite journal |author=Marson AG, Al-Kharusi AM, Alwaidh M, ''et al'' |title=The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial |journal=Lancet |volume=369 |issue=9566 |pages=1016–26 |year=2007 |pmid=17382828 |doi=10.1016/S0140-6736(07)60461-9}} [http://www.acpjc.org/Content/147/3/issue/ACPJC-2007-147-3-075.htm ACP Journal Club summary]</ref><ref name="pmid17903391">{{cite journal |author=Marson AG, Appleton R, Baker GA, ''et al'' |title=A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial |journal=Health technology assessment (Winchester, England) |volume=11 |issue=37 |pages=1–154 |year=2007 |pmid=17903391 |doi=}}</ref> | ||
* For idiopathic generalised epilepsy or difficult to classify epilepsy, "[[valproate]] remains the clinically most effective drug, although [[topiramate]] may be a cost-effective alternative for some patients". | |||
* For partial seizures, "[[lamotrigine]] may be a clinical and cost-effective alternative to the existing standard drug treatment, [[carbamazepine]]" | * For partial seizures, "[[lamotrigine]] may be a clinical and cost-effective alternative to the existing standard drug treatment, [[carbamazepine]]" | ||
==References== | ==References== | ||
Revision as of 13:18, 5 November 2007
Epilepsy is defined as "a disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns."[1]
Treatment
A randomized controlled trial concluded:[2][3]
- For idiopathic generalised epilepsy or difficult to classify epilepsy, "valproate remains the clinically most effective drug, although topiramate may be a cost-effective alternative for some patients".
- For partial seizures, "lamotrigine may be a clinical and cost-effective alternative to the existing standard drug treatment, carbamazepine"
References
- ↑ National Library of Medicine. Epilepsy. Retrieved on 2007-10-26.
- ↑ Marson AG, Al-Kharusi AM, Alwaidh M, et al (2007). "The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial". Lancet 369 (9566): 1016–26. DOI:10.1016/S0140-6736(07)60461-9. PMID 17382828. Research Blogging. ACP Journal Club summary
- ↑ Marson AG, Appleton R, Baker GA, et al (2007). "A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial". Health technology assessment (Winchester, England) 11 (37): 1–154. PMID 17903391. [e]